MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/80/0.1/20.12.24 | Delayed Börse Stuttgart 01:59:44 20/06/2024 pm IST | ||
| 0.47 EUR | +2.17% |
|
| Current month | -2.13% | ||
| 1 month | +6.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 0.47 | +2.17% |
| 19/24/19 | 0.46 | -4.17% |
| 18/24/18 | 0.48 | -11.11% |
| 17/24/17 | 0.54 | -1.82% |
| 14/24/14 | 0.55 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 01:59 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3F25 |
| ISIN | DE000MB3F254 |
| Date issued | 08/02/2023 |
| Strike | 80 $ |
| Maturity | 20/12/2024 (184 Days) |
| Parity | 10 : 1 |
| Emission price | 0.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.85 € |
|---|---|
| Lowest since issue | 0.048 € |
| Spread | 0.04 € |
| Spread % | 7.84% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157
USD
Average target price
174.4
USD
Spread / Average Target
+11.09%
- Stock Market
- Warrants
- Warrant
